// App-Quantinova.ai

2602 : Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.

Researchers

Presenter

  • David Fairman

Principal Investigators

  • Rajesh Narwal

  • Meina Liang

  • Aiman M. Shalabi

  • Carlos Chavez

  • Hong Lu

  • Min Pak

  • Andy Blake-Haskins

  • Jim Vasselli

  • Ramy A. Ibrahim

  • Lorin Roskos

  • Paul B. Robbins

  • Amy Schneider

Medical Centers

  • MedImmune LLC, Mountain View, CA

  • MedImmune, Cambridge, United KingdomMedImmune, Gaithersburg, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Soluble programmed death-ligand 1

Drug/Treatment

  • Durvalumab

Outcome

  • Positive

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Medimmune

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved